National Lipid Association Online |

Jump to Navigation

Facebook Connect

Forgot Your Password? |

Become a Member

Fall CLU

FCS Video

	NLA to Host Free PCSK9 CME/CE Webinar Aug. 8 Join Dr. Carl Orringer from University of Miami and Dr. Alan S. Brown from Advocate Lutheran General Hospital on Tuesday, August 8th at 6:00pm EST to learn about the National Lipid Association's recommendations update on the use of PCSK9 inhibitors in your adult high-risk patients with ASCVD,... read more
	Merck Provides Update on REVEAL Outcomes Study of Anacetrapib Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib met its primary endpoint, significantly reducing major coronary events (defined as the... read more
	JCL Impact Factor Rises to 5.812 The Journal of Clinical Lipidology announced on Monday its 2016 Impact Factor has risen to 5.812, up from 4.906 in 2015.
	National Lipid Association Announces Recipients of Inaugural Junior Faculty Research Awards The National Lipid Association (NLA) announced on Thursday the recipients of its inaugural Junior Faculty Research Awards for Clinical Science and Basic Science.
	National Lipid Association Releases Results of Survey on Barriers to PCSK9 Inhibitor Prescription Approval Process The National Lipid Association (NLA) released on Wednesday the results of its survey on the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor prescription approval process.
	New York Lipidologist Becomes President of the National Lipid Association The National Lipid Association (NLA) announced the election of new President James A. Underberg, MD, MS, FACPM, FACP, FASPC, FNLA, on Saturday at the 2017 Scientific Sessions in Philadelphia.
	National Lipid Association Releases Updated Recommendations on the Use of PCSK9 Inhibitors at the 15th Annual Scientific Session The National Lipid Association (NLA) assembled a panel of experts to update its guidance for the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy made in the NLA Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 in 2015.
	NLA Adds Trio of New Features to 2017 Scientific Sessions With the National Lipid Association’s 2017 Scientific Sessions in Philadelphia from May 18-21 fast approaching, NLA members have an annual meeting packed full of top insights from respected medical leaders to look forward to.